The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.

The latest price target for Genmab (NASDAQ: GMAB) was reported by Truist Securities on September 26, 2023. The analyst firm set a price target for $54.00 expecting GMAB to rise to within 12 months (a possible 56.34% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by Truist Securities, and Genmab reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $54.00. The current price Genmab (GMAB) is trading at is $34.54, which is within the analyst’s predicted range.